Recombinant Human TWEAK/TNFSF12

Catalog Number: 1090-TW/CF

DESCRIPTION

Source	*E. coli*-derived human TWEAK/TNFSF12 protein Arg93-His249, with an N-terminal Met and 6-His tag Accession # Q4ACW9
N-terminal Sequence Analysis	Met
Predicted Molecular Mass	18.3 kDa

SPECIFICATIONS

Activity	Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED_{50} for this effect is 0.200-4.00 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

Bioactivity



Recombinant Human TWEAK/TNFSF12 Protein Bioactivity Recombinant Human TWEAK/TNFSF12 (Catalog # 1090-TW/CF) stimulates cell proliferation in HUVEC human umbilical vein endothelial cells. The ED_{50} is 2-8 ng/mL.

SDS-PAGE



Recombinant Human TWEAK/TNFSF12 Protein SDS-PAGE 1 µg/lane of Recombinant Human TWEAK/TNFSF12 was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 19 kDa.

BACKGROUND

TWEAK is a type II transmembrane protein belonging to the TNF superfamily (1). It contains a short cytoplasmic domain (aa 1-18), the transmembrane domain (aa 19-42) and an extracellular domain (aa 43-249). The extracellular domains of human and murine TWEAK share 89% aa sequence identity. A soluble form of TWEAK is generated from the membrane-associated molecules by proteolytic cleavage after Arg 93 suggesting that TWEAK may have long-range effects. TWEAK is expressed widely in many tissues and cells. At least two receptors that bind TWEAK have been identified (2-4). Death Receptor 3 (DR3), also known as TNFRSF12, Apo-3, LARD, WSL-1 or TRAMP, is a TNF receptor superfamily member that is expressed predominantly in tissues with high lymphocyte content (2). It has been suggested that induction of cell death by TWEAK-DR3 interaction involves the activation of NF-κB. In cells that lack DR3, alternate pathways of TWEAK-induced cell death mediated by receptors distinct from DR3 have been suggested (5, 6). TWEAK receptor (TWEAKR, alternatively known as FN14), is a novel TNF receptor superfamily member that also binds TWEAK (3, 4). It is a mitogen-inducible gene that is expressed in fibroblasts, hepetocellular carcinomas and endothelial cells. TWEAK-TWEAKR interaction has been shown to play a role in endothelial cell growth and migration. This effect of TWEAK is not mediated by an up-regulation of VEGF (7).

References:

1. Chicheportiche, Y. *et al.* (1997) J. Biol Chem. **272**:32401.
2. Marsters, S. *et al.* (1998) Current Biol. **8**:525.
3. Wiley, S. R. *et al.* (2001) Immunity, **15**:837.
4. Feng, S.-L.Y. *et al.* (2000) Am J. Path. **156**:1253.
5. Nakayama, M. *et al.* (2002) J. Immunol. **168**:734.
6. Schneider, P. *et al.* (1999) Eur. J. Immunol., **29**:1785.
7. Lynch, C. *et al.* (1998) J. Biol. Chem. **274**:8455.

bio-techne®
Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449